BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 25598153)

  • 1. Successful treatment of kaposiform lymphangiomatosis with sirolimus.
    Wang Z; Li K; Yao W; Dong K; Xiao X; Zheng S
    Pediatr Blood Cancer; 2015 Jul; 62(7):1291-3. PubMed ID: 25598153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased vascularization of retroperitoneal kaposiform hemangioendothelioma induced by treatment with sirolimus explains relief of symptoms.
    Iacobas I; Simon ML; Amir T; Gribbin CE; McPartland TG; Kaufman MR; Calderwood S; Nosher JL
    Clin Imaging; 2015; 39(3):529-32. PubMed ID: 25662209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kaposiform lymphangiomatosis: unifying features of a heterogeneous disorder.
    Fernandes VM; Fargo JH; Saini S; Guerrera MF; Marcus L; Luchtman-Jones L; Adams D; Meier ER
    Pediatr Blood Cancer; 2015 May; 62(5):901-4. PubMed ID: 25307772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case of kaposiform haemangioendothelioma successfully and safely treated with sirolimus.
    Wlodek C; Burt H; Shaw L
    Clin Exp Dermatol; 2017 Oct; 42(7):825-827. PubMed ID: 28703334
    [No Abstract]   [Full Text] [Related]  

  • 5. Successful Management of Pancreatic Kaposiform Hemangioendothelioma With Sirolimus: Case Report and Literature Review.
    Wang C; Li Y; Xiang B; Li F; Chen S; Li L; Ji Y
    Pancreas; 2017; 46(5):e39-e41. PubMed ID: 28426496
    [No Abstract]   [Full Text] [Related]  

  • 6. Sirolimus in the Treatment of Vascular Anomalies.
    Triana P; Dore M; Cerezo VN; Cervantes M; Sánchez AV; Ferrero MM; González MD; Lopez-Gutierrez JC
    Eur J Pediatr Surg; 2017 Feb; 27(1):86-90. PubMed ID: 27723921
    [No Abstract]   [Full Text] [Related]  

  • 7. Vascular Anomalies: Diagnosis of Complicated Anomalies and New Medical Treatment Options.
    Adams DM; Ricci KW
    Hematol Oncol Clin North Am; 2019 Jun; 33(3):455-470. PubMed ID: 31030813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirolimus for Kaposiform Hemangioendothelioma With Kasabach-Merritt Phenomenon in Two Infants.
    Wang Y; Kong L; Sun B; Cui J; Shen W
    J Craniofac Surg; 2020 Jun; 31(4):1074-1077. PubMed ID: 32176003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of topical sirolimus on superficial Kaposiform haemangioendothelioma.
    Liu YX; Zhang J; Nie XL; Chen YL; Wang ZY; Xu ZG
    Australas J Dermatol; 2021 May; 62(2):e329-e331. PubMed ID: 33216947
    [No Abstract]   [Full Text] [Related]  

  • 10. Low dose sirolimus treatment for refractory tufted angioma and congenital kaposiform hemangioendothelioma, both with Kasabach-Merritt phenomenon.
    Mariani LG; Schmitt IR; Garcia CD; Kiszewski AE
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27810. PubMed ID: 31087627
    [No Abstract]   [Full Text] [Related]  

  • 11. Successful treatment of Kaposiform hemangioendothelioma with everolimus.
    Uno T; Ito S; Nakazawa A; Miyazaki O; Mori T; Terashima K
    Pediatr Blood Cancer; 2015 Mar; 62(3):536-8. PubMed ID: 25306933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kaposiform haemangioendothelioma in an adult: lack of response to topical sirolimus and response to radiotherapy.
    Der Sarkissian SA; Wong XL; Kossard S; Hong A; Sebaratnam DF
    Clin Exp Dermatol; 2022 Jan; 47(1):192-193. PubMed ID: 34480811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon in an infant: Successful treatment with prednisolone, vincristine, and addition of sirolimus.
    Cashell J; Smink GM; Helm K; Xavier F
    Pediatr Blood Cancer; 2018 Dec; 65(12):e27305. PubMed ID: 30070028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sirolimus as initial therapy for kaposiform hemangioendothelioma and tufted angioma.
    Wang H; Guo X; Duan Y; Zheng B; Gao Y
    Pediatr Dermatol; 2018 Sep; 35(5):635-638. PubMed ID: 29999213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapidly enlarging "bruise" on the back of an infant. Kaposiform hemangioendothelioma complicated by Kasabach-Merritt syndrome.
    Chan S; Cassarino DS
    JAMA Dermatol; 2013 Nov; 149(11):1337-8. PubMed ID: 24005816
    [No Abstract]   [Full Text] [Related]  

  • 16.
    Russell TB; Rinker EK; Dillingham CS; Givner LB; McLean TW
    Pediatrics; 2018 Apr; 141(Suppl 5):S421-S424. PubMed ID: 29610164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retroperitoneal kaposiform hemangioendothelioma complicated by Kasabach-Merritt phenomenon and obstructive jaundice: A retrospective series of 3 patients treated with sirolimus.
    Yao W; Li K; Wang Z; Dong K; Zheng S
    Pediatr Dermatol; 2020 Jul; 37(4):677-680. PubMed ID: 32212177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: successful treatment with sirolimus.
    Reichel A; Hamm H; Wiegering V; Wiewrodt B; Neubauer H; Ernestus K; Winkler B
    J Dtsch Dermatol Ges; 2017 Mar; 15(3):329-331. PubMed ID: 28220608
    [No Abstract]   [Full Text] [Related]  

  • 19. Sirolimus Treatment of an Infant With Intrathoracic Kaposiform Hemangioendothelioma Complicated by Life-threatening Pleural and Pericardial Effusions.
    Duan L; Renzi S; Weidman D; Waespe N; Chami R; Manson D; Cada M; Carcao M
    J Pediatr Hematol Oncol; 2020 Jan; 42(1):74-78. PubMed ID: 30044355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Kasabach-Merritt phenomenon following vaccination: More than a coincidence?
    Ji Y; Chen S; Yang K; Xia C; Peng S
    J Dermatol; 2018 Oct; 45(10):1203-1206. PubMed ID: 30118141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.